A Phase 1B/2, Open-Label, Multicentre Study Assessing The Safety, Tolerability, Pharmacokinetics, And Preliminary Anti-Tumour Activity Of Medi4736 In Combination With Azd9150 Or Azd5069 In Patients With Advanced Solid Malignancies And Subsequently C
Posted Date: May 12, 2018
- Investigator: Trisha Wise-Draper
- Specialties: Hematology/Oncology, Oncology, Cancer
- Type of Study: Drug
The main purpose of this study is to see if the AZD9150 and AZD5069 study drugs (alone or in combination with MEDI4736) shrink tumors like yours and by how much. This study is also being done to measure levels of the study drugs in the blood at different times and see how the body accepts and removes the study drugs (called pharmacokinetics or “PK”); to see the effect that eating food has on the PK of AZD5069; to see whether (and how) the drugs change blood cells and other parts of your blood (called pharmacodynamics or “PD”); to see whether elements of your blood and tumor cells called “biomarkers” predict or change with any response to the study drugs; and to see if your body develops any “immunity” (ie, resistance) to MEDI4736 or AZD9150. There are additional parts of the study that are optional, and you will need to sign separate Informed Consent Forms if you choose to participate in them.
To Be Eligible, Patients Must Have Squamous Cell Carcinoma Of The Head And Neck That Is Either Recurrent And/Or Metastatic And Is Not Able To Be Cured By Surgery Or Radiation.
Head And Neck, Cancer, D5660c00004, Phase I, Solid Tumor
For More Information:
Uc Cancer Institute